ArticleJAMA network open2024
Mortality Risk Among Women With Premenstrual Disorders in Sweden.
Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prevalence, Risk Factors, and Treatments for Suicidality in People Living with Premenstrual Dysphoric Disorder (PMDD): A Systematic Review.Administration and policy in mental health · 2026Pooled it
- Emotion regulation in Premenstrual Dysphoric Disorder and Premenstrual Syndrome: a systematic review.BMC psychology · 2025Pooled it
- A Genome-Wide Association Study of Premenstrual Symptoms in Two Nordic Populations.Biological psychiatry global open science · 2026Article
- Wearable-measured heart rate variability and premenstrual disorder symptoms across menstrual cycle.Archives of women's mental health · 2026Article
- Bidirectional Association Between Premenstrual Disorders and Psychiatric Disorders.JAMA network open · 2026Article
- Self-Guided Mental Health Interventions for Premenstrual Mood Symptoms.Current psychiatry reports · 2025Review
- Job Stress, Psychological Distress, and Menstruation-Related Symptoms in Female Workers: A Cross-Sectional Study.BJOG : an international journal of obstetrics and gynaecology · 2025Article
- Premenstrual disorders and risk of cardiovascular diseases.Nature cardiovascular research · 2025Article
- Premenstrual disorders and risk of sick leave and unemployment: a prospective cohort study of 15 857 women in Sweden.BMJ mental health · 2025Article
- Suicidality should be considered for inclusion in the diagnostic criteria for PMDD.The lancet. Psychiatry · 2025Article
- Improving care experiences for premenstrual symptoms and disorders in the United Kingdom (UK): a mixed-methods approach.BMC health services research · 2025Article
- Polycystic Ovary Syndrome and the Risk of Premenstrual Disorders: A Nationwide Register-Based Study in Sweden.Depression and anxiety · 2025Article
- Identifying predictors of formal help-seeking for premenstrual symptoms: A machine learning analysis of symptom, functional impairment and barriers data.PLOS mental health · 2025Article
- Prevalence of premenstrual syndrome, premenstrual dysphoric disorder, and dysmenorrhea in nursing students: a systematic review, meta-analysis, and evidence-based recommendations.Frontiers in global women's health · 2025Review
- Error in Affiliations.JAMA network open · 2024Article
- Patient-identified priorities for a mental health program tailored to premenstrual dysphoric disorder.Women's health (London, England)Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Premenstrual disorders (PMDs) adversely affect the quality of life of millions of women worldwide, yet research on the long-term consequences of PMDs is limited, and the risk of mortality has not been explored. Objective: To estimate the associations of PMDs with overall and cause-specific mortality. Design, Setting, and Participants: This nationwide, population-based, matched cohort study used data from population and health registers in Sweden. Participants included women of reproductive age with a first diagnosis of PMDs between January 1, 2001, and December 31, 2018. Data analysis was performed from September 2022 to April 2023. Exposures: PMDs were identified through inpatient and outpatient diagnoses and drug dispensing. Main Outcomes and Measures: Dates of death and underlying causes were ascertained from the National Cause of Death Register. Conditional Cox regression was used to estimate the hazard ratios (HRs) of overall and cause-specific death (eg, death due to natural or nonnatural cause, suicide, or cardiovascular events), adjusting for age, socioeconomic status, and somatic and psychiatric comorbidities; in a separate sibling comparison, models were also adjusted for all factors that sisters share. Results: A total of 67 748 women with clinically diagnosed PMDs and 338 740 matched unaffected women were included, for a total of 406 488 women. Women with PMDs received a diagnosis at a mean (SD) age of 35.8 (8.2) years. During a mean (SD) follow-up of 6.2 (4.6) years (range, 1-18 years), 367 deaths were observed among women with PMDs (rate, 8.4 deaths per 10 000 person-years; 95% CI, 7.6-9.3 deaths per 10 000 person-years), and 1958 deaths were observed among women without PMDs (rate, 9.1 deaths per 10 000 person-years; 95% CI, 8.7-9.6 deaths per 10 000 person-years). Compared with unaffected women, women with PMDs had increased risk of death due to nonnatural causes (HR, 1.59; 95% CI, 1.25-2.04), particularly suicide (HR, 1.92; 95% CI, 1.43-2.60), but they did not have increased risk of overall mortality (adjusted HR, 0.91; 95% CI, 0.82-1.02). Notably, women who received a diagnosis before the age of 25 years experienced higher all-cause mortality (HR, 2.51; 95% CI, 1.42-4.42) and death from both suicide (HR, 3.84; 95% CI, 1.18-12.45) and natural causes (HR, 2.59; 95% CI, 1.21-5.54). Conclusions and Relevance: The findings of this matched cohort study suggest that women with PMDs are not at increased risk of early death overall. However, the risk was elevated among young women and for death by suicide. This supports the importance of careful follow-up for young patients and highlights the need to develop suicide prevention strategies for all women with PMDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.